Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUBVENITE vs FINTEPLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.
Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.
Treatment of Parkinson's disease as monotherapy or adjunct to levodopa,Off-label: treatment of major depressive disorder (limited evidence)
Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older,Treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older
Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.
0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.
Terminal elimination half-life is approximately 70-90 hours in adults with normal renal function, allowing once-daily dosing.
Terminal elimination half-life approximately 9 hours in adults; at steady state, accumulation minimal with twice-daily dosing.
Rasagiline is primarily metabolized by CYP1A2 to its major metabolite, 1-(R)-aminoindan. Minor pathways involve CYP2D6 and conjugation.
Fenfluramine is primarily metabolized by CYP1A2, CYP2B6, and CYP2D6 to its active metabolite norfenfluramine. Norfenfluramine is further metabolized by CYP2D6 and other enzymes.
Renal elimination of unchanged drug accounts for approximately 45-50% of the administered dose; fecal elimination via biliary excretion accounts for approximately 40-45%.
Renal: 65% as unchanged drug; Fecal: 29% primarily as metabolites; Biliary: negligible.
Approximately 95% bound to plasma proteins, primarily albumin.
Approximately 55% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 3-7 L/kg, indicating extensive tissue distribution.
Apparent volume of distribution (Vd/F) approximately 2.5–3.5 L/kg, suggesting extensive extravascular distribution.
Oral bioavailability is approximately 50-60%.
Oral bioavailability approximately 80% (relatively high first-pass metabolism: moderate).
GFR 30-89 m L/min: No adjustment. GFR 15-29 m L/min: Reduce dose by 50%; increase dosing interval to every 12 hours. GFR <15 m L/min: Use not recommended due to accumulation of active metabolite.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
Child-Pugh A (mild): No adjustment. Child-Pugh B (moderate): Reduce starting dose by 50%; titrate cautiously. Child-Pugh C (severe): Avoid use.
Mild hepatic impairment (Child-Pugh A): maximum dose 11 mg/day. Moderate to severe (Child-Pugh B or C): not recommended.
Approved for ages ≥6 years for breakthrough cancer pain: Dose based on prior opioid requirement; typical starting dose 2 mcg/kg sublingually; titrate by 2 mcg/kg as needed; maximum single dose 10 mcg/kg. Maximum 4 doses per day.
For patients weighing 10-50 kg: initial 0.05 mg/kg twice daily; titrated to 0.1 mg/kg twice daily (target), may increase to 0.2 mg/kg twice daily (max). For patients weighing ≥50 kg: same as adult dosing (max 16 mg/day). Not established for weight <10 kg.
Use with caution; start at lowest available dose (2 mg sublingually). Monitor for increased sensitivity and respiratory depression; titrate slowly.
No specific dose adjustment; start at low end of dosing range due to greater frequency of decreased hepatic/renal function and concomitant disease.
No FDA black box warning.
Valvular heart disease and pulmonary arterial hypertension: FINTEPLA is associated with valvular heart disease (e.g., mitral and aortic regurgitation) and pulmonary arterial hypertension. Patients must undergo echocardiography before starting treatment, at 3 months, and every 6-12 months thereafter.
Hypertensive crisis with tyramine-rich foods, beverages, or drugs (e.g., sympathomimetics, other MAOIs),Serotonin syndrome when used with serotonergic drugs,May cause hallucinations, confusion, or impulse control disorders,May exacerbate dyskinesia when used with levodopa,Caution in patients with hepatic impairment
Valvular heart disease and pulmonary arterial hypertension: monitor with echocardiography,Increased intraocular pressure: caution in patients with glaucoma,Suicidal thoughts and behavior: monitor for worsening depression and suicidality,Dizziness, somnolence, and fatigue: may impair ability to drive or operate machinery,Decreased appetite and weight loss: monitor weight, especially in pediatric patients,Potential for abuse and dependence: controlled substance (Schedule IV)
Concurrent use of other MAOIs (including linezolid or IV methylene blue),Concurrent use of sympathomimetic amines (e.g., amphetamines, cold products),Concurrent use of pethidine, SSRIs, SNRIs, tricyclic antidepressants, or St. John's wort,Pheochromocytoma,Severe hepatic impairment
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation of an MAOI,Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs) due to risk of serotonin syndrome,Hypersensitivity to fenfluramine or any component of the formulation
No significant food interactions. Administer with food to reduce flushing and GI symptoms. Avoid alcohol as it may worsen flushing or liver enzyme elevation.
Avoid grapefruit and grapefruit juice as they are CYP1A2 inhibitors and may increase fenfluramine exposure. No other significant food interactions reported.
First trimester: Sufficient evidence of teratogenicity in animal studies; human data limited but risk cannot be excluded. Second and third trimesters: No specific fetal anomalies reported, but potential for neonatal adaptation syndrome at delivery.
FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In animal studies, fenfluramine caused embryofetal mortality and structural abnormalities at clinically relevant doses. During the second and third trimesters, exposure may lead to fetal growth restriction and neurodevelopmental effects. Use during pregnancy is contraindicated unless no safer alternative exists.
Excreted into breast milk; M/P ratio not determined. Due to risk of serious adverse reactions in breastfed infants, breastfeeding is not recommended during therapy.
Fenfluramine is excreted into human breast milk; the milk-to-plasma (M/P) ratio is approximately 0.5. Based on limited data, the relative infant dose is estimated to be <10% of the maternal weight-adjusted dose. However, prolonged exposure may cause adverse effects in the infant (e.g., irritability, feeding difficulties). Breastfeeding is not recommended during FINTEPLA therapy due to potential for serious adverse reactions.
No formal studies; due to increased plasma volume and renal clearance in pregnancy, therapeutic effect may decrease. Consider monitoring drug levels or dose adjustment based on clinical response, but no established dosing schedule.
No specific dose adjustments are recommended for pregnancy due to lack of pharmacokinetic studies. However, physiological changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may necessitate therapeutic drug monitoring and dose titration. Use lowest effective dose and consider alternative agents if possible.
Subvenite is a brand of dimethyl fumarate, used for relapsing forms of multiple sclerosis. Titrate starting dose to minimize flushing and GI adverse effects. Administer with food to reduce flushing. Monitor absolute lymphocyte count (ALC) regularly due to risk of lymphopenia. Consider PML risk with prolonged lymphopenia. Discontinue if ALC < 0.5x10^9/L for >6 months. Non-enteric coated aspirin 325 mg may reduce flushing severity when taken 30 minutes prior to dose.
FINTEPLA (fenfluramine) is indicated for seizures associated with Dravet syndrome. Monitor for valvular heart disease and pulmonary arterial hypertension due to serotonergic effects; obtain baseline and periodic echocardiograms. Titrate slowly to minimize appetite suppression and weight loss. Avoid concurrent use with monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs due to risk of serotonin syndrome. Dose adjustment required in hepatic impairment.
Take Subvenite exactly as prescribed, with or without food. Swallow capsules whole; do not crush or chew.,Flushing and stomach upset are common, especially at start. Taking with food and using aspirin (if recommended) can help.,You may need blood tests to monitor white blood cell counts before and during treatment.,Report any signs of infection (fever, persistent cough, fatigue) or new neurological symptoms.,Do not stop or change dose without consulting your doctor.,Store capsules at room temperature away from moisture and heat.
Take exactly as prescribed; do not stop abruptly as withdrawal may increase seizure frequency.,Common side effects include decreased appetite, weight loss, diarrhea, and fatigue.,Report any signs of heart problems such as shortness of breath, chest pain, or swelling of ankles.,Avoid grapefruit and grapefruit juice during treatment as it may increase drug levels.,Women of childbearing potential should use effective contraception due to potential fetal harm.,Do not drive or operate heavy machinery until you know how the medication affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUBVENITE vs FINTEPLA, answered by our medical review team.
SUBVENITE is a Antiepileptic that works by SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.. FINTEPLA is a Antiepileptic that works by Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUBVENITE and FINTEPLA depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUBVENITE is: Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.. The standard adult dose of FINTEPLA is: 0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUBVENITE and FINTEPLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUBVENITE is classified as Category C. First trimester: Sufficient evidence of teratogenicity in animal studies; human data limited but risk cannot be excluded. Second and third trimesters: No specific fetal anomalies r. FINTEPLA is classified as Category C. FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In ani. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.